Torin 1

[1]Thoreen CC, et al, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem, 2009, 284 (12), 8023-8032.|[2]Liu Q, et al. Discovery of 1- (4- (4-propionylpiperazin-1-yl) -3- (trifluoromethyl) phenyl) -9- (quinolin-3-yl) benzo[h][1,6]naphthyridin-2 (1H) -one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53 (19) :7146-55.|[3]Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102 (4) :755-764.|[4]Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. Cell Metab. 2018 Jan 9;27 (1) :118-135.e8.